



For Immediate Release

November 18, 2024

Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference

Vancouver, B.C. – As the global leader in lipid nanoparticle (LNP) delivery systems, Acuitas Therapeutics, Inc. shared new research data with scientists from around the world attending the 12th International mRNA Health Conference in Boston, Massachusetts.

Dr. Ying Tam, Chief Scientific Officer, presented as part of the scientific program, and Dr. Ghania Chikh, Senior Director of Vaccine Development, delivered a poster presentation at the conference.

Dr. Tam's presentation covered recent developments to optimize the clinical application of mRNA therapeutics. Highlights include: (1) New LNP formulations for intravenous delivery providing improved potency and safety and benchmarked against an Intellia clinical LNP; (2) identification of improved LNP formulations for multivalent infectious disease vaccines; and (3) LNP systems directed to target specific cells in the circulation, employing targeting ligands suitable for pharmaceutical manufacture. You can find his presentation [here](#).

Dr. Chikh's poster presentation was on the identification of novel lipids with substantially improved activity for prophylactic vaccines. Using a highly-selective SAR screening model, the team identified new compounds that induce up to 12-fold higher neutralization antibody titres compared to ALC-0315 (ionizable lipid used in COMIRNATY®) in preclinical models. These next-generation vaccine LNP are designed specifically to enable multivalent vaccines as further demonstrated in a preclinical study comparing neutralization titres after administration of LNP containing single and multivalent mRNA constructs. You can find this presentation [here](#).

About the International mRNA Health Conference

The [International mRNA Health Conference](#) is the premier meeting destination for industry and academic professionals to explore the rapidly advancing science and business of mRNA medicines. It provides participants with an opportunity to learn more about developments in mRNA technologies through scientific presentations by experts in the field and extensive networking opportunities. The event brings together over 900 attendees from both academic institutions and leading pharma and biotech companies.



About Acuitas Therapeutics

Vancouver-based [Acuitas Therapeutics](#) is the global leader in lipid nanoparticle (LNP) technology and partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical development and commercialization. Acuitas' LNP technology is clinically validated, enabling Alnylam Pharmaceuticals' ONPATRO® for the treatment of people with a rare genetic and otherwise fatal disorder known as transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in over 180 countries. Acuitas has also helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is currently focused on further innovations to its LNP carriers to advance the development of novel gene therapies, such as epigenetic medicines, to modulate gene expression without genetic editing to treat a range of diseases, including cancer. In addition, Acuitas works on identification of potent new lipids to enable partners to develop improved and new vaccines to prevent a range of infectious diseases (i.e., malaria, HIV/AIDS and tuberculosis), multivalent vaccines, and novel therapeutic vaccines against cancer, including personalized cancer vaccines.

-END-